Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 12/2019

01-12-2019 | Prostate Cancer | Original Article

Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment

Authors: Vassiliki Pasoglou, Nicolas Michoux, Julien Van Damme, Sandy Van Nieuwenhove, Marin Halut, Perrine Triqueneaux, Bertrand Tombal, Frédéric E. Lecouvet

Published in: World Journal of Urology | Issue 12/2019

Login to get access

Abstract

Purpose

It is generally accepted that when metastases develop in a patient with biochemical recurrence of prostate cancer (PCa), they follow a centrifuge pattern of seeding from the pelvis and that most patients enter the disease as oligometastatic. In this study, we used whole-body magnetic resonance imaging (WB-MRI) to assess the anatomical distribution of oligo- and polymetastatic disease and the impact of the initial treatment on this distribution in patients.

Materials and methods

WB-MRI examinations of patients with a rising prostate-specific antigen (PSA) after radical treatment by surgery or/and radiotherapy were analyzed for disease recurrence. The patients were separated into three groups, based on the primary treatment: patients treated by radical prostatectomy without radiotherapy and with/without lymph node dissection (RP), patients treated only by radiotherapy or hormono-radiotherapy (RT) and patients treated with radical prostatectomy and adjuvant or salvage radiotherapy (RP + RT). Patients with ≤ 5 bone or/and node metastases were considered oligometastatic. Regional distributions of bone and lymph nodes metastases were reported using anatomical diagrams. Univariate and multivariable logistic regressions were performed to identify prognostic factors of relapse.

Results

The primary treatment (RP, RT, RP + RT), Gleason score, PSA at relapse, time between first diagnosis and recurrence did not influence the metastatic status (oligo vs. polymetastatic). Oligometastatic patients showed different distribution of bone metastases compared to the polymetastatic ones and the distribution of the oligometastatic disease was not influenced by the primary treatment.

Conclusions

In this WB-MRI-based study, there was no evidence that the primary treatment influenced the metastatic status of the patient or the distribution of the oligometastatic disease.
Literature
1.
Roehl KA et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 172(3):910–914PubMedCrossRef
2.
3.
Padhani AR et al (2017) Rationale for modernising imaging in advanced prostate cancer. Eur Urol Focus 3(2–3):223–239PubMedCrossRef
4.
Lecouvet FE et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99 m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62(1):68–75PubMedCrossRef
5.
Gupta SK et al (2017) Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning. Int J Radiat Oncol Biol Phys 99(3):701–709PubMedCrossRef
6.
Lepinoy A et al (2014) Pattern of occult nodal relapse diagnosed with (18)F-fluoro–choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. Radiother Oncol 111(1):120–125PubMedCrossRef
7.
Ost P et al (2016) Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol R Coll Radiol 28(9):e115–e120PubMedCrossRef
8.
Sobol I et al (2017) Contemporary mapping of post-prostatectomy prostate cancer relapse with (11)C-Choline positron emission tomography and multiparametric magnetic resonance imaging. J Urol 197(1):129–134PubMedCrossRef
9.
Larbi A et al (2016) Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: therapeutic perspectives on targeted management of oligometastatic disease. Prostate 76(11):1024–1033PubMedCrossRef
10.
Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRef
11.
Koh DM, Hughes M, Husband JE (2006) Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Abdom Imaging 31(6):632–643PubMedCrossRef
12.
Ahmed KA et al (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2:215PubMedCrossRef
13.
14.
Mehta CR, Patel NR (1983) A network algorithm for performing Fisher’s exact test in r c contingency tables. J Am Stat Assoc 78:427–434
15.
Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17(8):857–872PubMedCrossRef
16.
Pampel FC (2000) Logistic regression: a primer. Quantitative applications in the social sciences. Thousand oaks. Sage Publications, CaliforniaCrossRef
17.
Tosoian JJ et al (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15–25PubMedCrossRef
18.
Singh D et al (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58(1):3–10PubMedCrossRef
19.
20.
Gillessen S et al (2018) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73(2):178–211PubMedCrossRef
21.
Parker CC et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366PubMedPubMedCentralCrossRef
22.
Tamoto E et al (2004) Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res 10(11):3629–3638PubMedCrossRef
23.
24.
25.
Murphy DG, Sweeney CJ, Tombal B (2017) “Gotta Catch ‘em All”, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol 72(1):1–3PubMedCrossRef
26.
Ost P et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453PubMedCrossRef
27.
Muacevic A et al (2013) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 31(4):455–460PubMedCrossRef
28.
Richard PJ, Rengan R (2016) Oligometastatic non-small-cell lung cancer: current treatment strategies. Lung Cancer (Auckl) 7:129–140
29.
Simmonds PC et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94(7):982–999PubMedPubMedCentralCrossRef
30.
Graves A et al (2013) Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther 2:73–90PubMedPubMedCentral
31.
Lecouvet FE et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25(22):3281–3287PubMedCrossRef
32.
33.
Padhani AR et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1):81–92PubMedPubMedCentralCrossRef
34.
Park SY et al (2018) Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology 288(2):495–505PubMedCrossRef
35.
Dyrberg E et al (2018) (68)Ga-PSMA-PET/CT in comparison with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29:1221–1230PubMedCrossRef
36.
Pasoglou V et al (2014) One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? Prostate 74(5):469–477PubMedCrossRef
37.
Pasoglou V et al (2015) Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 275(1):155–166PubMedCrossRef
38.
Lecouvet FE et al (2018) Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC imaging group. Lancet Oncol 19(10):e534–e545PubMedCrossRef
39.
Parker WP et al (2017) Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol 71(3):340–348PubMedCrossRef
40.
Soldatov A et al (2019) Patterns of progression after (68)Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 103(1):95–104PubMedCrossRef
41.
Rischke HC et al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 191(4):310–320PubMedCrossRef
42.
Meijer HJ et al (2013) Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiother Oncol 106(1):59–63PubMedCrossRef
Metadata
Title
Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment
Authors
Vassiliki Pasoglou
Nicolas Michoux
Julien Van Damme
Sandy Van Nieuwenhove
Marin Halut
Perrine Triqueneaux
Bertrand Tombal
Frédéric E. Lecouvet
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 12/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02700-2

Other articles of this Issue 12/2019

World Journal of Urology 12/2019 Go to the issue

Letter to Editor

The effect of platelet-rich plasma injection on post-internal urethrotomy stricture recurrence

Original Article

Artificial urinary sphincter longevity following transurethral resection of the prostate in the setting of prostate cancer

Original Article

CD163+ macrophages predict a poor prognosis in patients with primary T1 high-grade urothelial carcinoma of the bladder

Original Article

External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy

Original Article

Impact of routine imaging in the diagnosis of recurrence for patients with localized and locally advanced renal tumor treated with nephrectomy

Original Article

The role of metastatic burden in cytoreductive/consolidative radical cystectomy